

## Newborn Screening ACT Sheet

### [Elevated C5-OH Acylcarnitine]

#### Organic Acidemias

**Differential Diagnosis:** 3-methylcrotonyl-CoA carboxylase (MCC) deficiency, maternal MCC deficiency, **3-hydroxy-3-methylglutaryl-CoA lyase (HMG) deficiency**;  $\beta$ -ketothiolase (BKT) deficiency; multiple carboxylase deficiency (MCD) (holocarboxylase synthetase deficiency [HCS] or biotinidase deficiency [BTD]), 2-methyl-3-hydroxybutyric acidemia (MHBD), 3-methylglutaconic aciduria (MGA), and MT-ATP6 related mitochondrial disorders.

**Condition Description:** Elevated C5-OH is associated with a group of organic acid disorders caused by a deficiency of an enzyme involved in the catabolism of branched chain amino acids. In most of the disorders, potentially toxic metabolites accumulate with variable clinical presentations. Each of the disorders is caused by a deficiency of the relevant enzyme. Of these disorders, MCC deficiency is the most common. HMG and HCS deficiencies can present acutely in the neonatal period.

#### **You Should Take the Following IMMEDIATE Actions:**

- Inform family of the newborn screening result.
- Ascertain clinical status (poor feeding, vomiting, lethargy).
- Consult with pediatric metabolic specialist the same day.
- Evaluate the newborn (hypoglycemia, ketonuria, metabolic acidosis). If any of these findings are present or if the newborn is ill, transport to a hospital for further treatment in consultation with the metabolic specialist.
- Initiate confirmatory/diagnostic testing as recommended by the specialist.
- Provide the family with basic information about the possible diagnoses and their management, including the need for urgent treatment of metabolic acidosis.
- Report final diagnostic outcome to newborn screening program.

**Diagnostic Evaluation: Plasma acylcarnitine profile:** C5-OH is elevated in all conditions; C5:1 (tiglylcarnitine) is also elevated in BKT deficiency. **Urine organic acids** demonstrate abnormal patterns characteristic of each condition. **Urine organic acids** and **plasma acylcarnitines** performed on infant and mother are warranted to evaluate for maternal MCC deficiency. **Serum biotinidase** identifies biotinidase deficiency. **Plasma amino acids** may demonstrate reduced citrulline in MT-ATP6-related disorders. **Enzymatic and molecular genetic testing** may be required.

**Clinical Considerations:** MCC deficiency is the most common of these disorders and most individuals with this diagnosis remain asymptomatic. Neonates with HMG and HCS deficiencies can present acutely with feeding difficulties, hypotonia, lethargy, and seizures; avoidance of fasting in these neonates is essential. Clinical features vary among the other conditions and can include episodes of hypoglycemia, lethargy, and hypotonia occurring during infancy and/or childhood. MGA comprises a heterogeneous group of disorders associated with diminished mitochondrial function. MT-ATP6-related mitochondrial disorders have been associated with Leigh syndrome, a neurodegenerative disorder. There is treatment available that is specific to each condition.

#### **Additional Information:**

[How to Communicate Newborn Screening Results](#)

**Emergency Protocols (New England Consortium of Metabolic Programs)** ([HMG](#) | [MCC](#))

**Gene Reviews** ([BTD](#))

**Medline Plus** ([HMG](#) | [MCC](#) | [BKT](#) | [HCS](#) | [BTD](#) | [MGA](#) | [MT-ATP6-related mitochondrial disease/Leigh syndrome](#))

**Condition Information for Families- HRSA Newborn Screening Clearinghouse** ([HMG](#) | [MCC](#) | [BKT](#) | [MCD](#) | [HCS](#) | [BTD](#) | [MGA](#))

#### **Referral (local, state, regional, and national):**

[Find a Genetics Clinic Directory](#)

[Genetic Testing Registry](#)

## [Elevated C5-OH Acylcarnitine] 3-hydroxy-3-methylglutaryl-CoA lyase (HMG) deficiency

### State and Other Resources

#### State Newborn Screening Program

Newborn Screening, State of Rhode Island Department of Health  
401-921-7619, [health.ri.gov/newbornscreening/](http://health.ri.gov/newbornscreening/)

#### Genetics/Metabolic Consultants

Division of Genetics, Lifespan Physician's Group, Hasbro Children's Hospital  
401-444-4000, [www.lifespan.org/centers-services/childrens-neurodevelopment-center/genetics-and-dysmorphology](http://www.lifespan.org/centers-services/childrens-neurodevelopment-center/genetics-and-dysmorphology)

#### Information for Clinicians and Families

Rhode Island Medical Home Portal (see Newborn Disorders and Parents & Families sections)  
[ri.medicalhomeportal.org/newborn/hmg-coa-lyase-deficiency](http://ri.medicalhomeportal.org/newborn/hmg-coa-lyase-deficiency)

#### Parent/Family Support

Organic Acidemia Association  
[www.oaanews.org/hmg.html](http://www.oaanews.org/hmg.html)

### National Resources (with web addresses)

#### Additional Information

How to Communicate Newborn Screening Results

[www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/Resources/achdnc-communication-guide-newborn.pdf](http://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/Resources/achdnc-communication-guide-newborn.pdf)

Emergency Protocols (New England Consortium of Metabolic Programs)

[www.newenglandconsortium.org/3hmg](http://www.newenglandconsortium.org/3hmg)

GARD (Genetic and Rare Diseases Information Center)

<https://rarediseases.info.nih.gov/diseases/8387/hmg-coa-lyase-deficiency>

Medline Plus

[medlineplus.gov/genetics/condition/3-hydroxy-3-methylglutaryl-coa-lyase-deficiency/](http://medlineplus.gov/genetics/condition/3-hydroxy-3-methylglutaryl-coa-lyase-deficiency/)

Condition Information for Families-HRSA Newborn Screening Clearinghouse

[newbornscreening.hrsa.gov/conditions/3-hydroxy-3-methylglutaryl-coa-lyase-deficiency](http://newbornscreening.hrsa.gov/conditions/3-hydroxy-3-methylglutaryl-coa-lyase-deficiency)

#### Referral (local, state, regional and national)

Find a Genetics Clinic Directory

[clinics.acmg.net](http://clinics.acmg.net)

Genetic Testing Registry

[www.ncbi.nlm.nih.gov/gtr/](http://www.ncbi.nlm.nih.gov/gtr/)